On July 28, 2025, Quanterix Corporation announced the commercial launch of two novel phospho-tau assays: p-Tau 205 and p-Tau 212. These new assays expand the company's market-leading portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration.
Developed on Quanterix’s ultra-sensitive Simoa platform, these assays enable the precise detection of tau phosphorylation sites, which are increasingly associated with early and progressive stages of Alzheimer’s disease. This empowers researchers to explore novel disease mechanisms and refine patient stratification.
The new p-Tau 205 and p-Tau 212 assays are available for use on the HD-X or SR-X instruments or through Quanterix's CLIA-licensed Accelerator Lab. The company also highlighted that its recent acquisition of Akoya Biosciences, with its Human FFPE Neurobiology Panel, complements the Simoa platform by enabling high-plex, spatially resolved analysis in brain tissue.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.